Trillium Therapeutics Mutual Funds

Health Care & Life Sciences » Biotechnology | Trillium Therapeutics Inc.

Trillium Therapeutics Inc. | Mutual Funds

Name

Shares Held

% Shares Out

Change In Shares

% of Assets

As of Date

Tekla Healthcare Investors

315,000

2.18%

-35,000

0.17%

12/31/2017

Candriam Equities L - Biotechnology

94,000

0.65%

0.04%

07/31/2018

Fidelity Nasdaq Composite Index

10,086

0.07%

07/31/2018

Tekla Life Sciences Investors

-150,000

12/31/2017

Janus Capital Funds Plc - Global Life Sciences Fund

-544,293

12/31/2017

-125,390

06/30/2018

View Profile

Address	2488 Dunwin Drive Mississauga Ontario L5L 1J9 Canada
Employees	-
Website	http://www.trilliumtherapeutics.com
Updated	07/08/2019
Trillium Therapeutics Inc. is a clinical stage immuno-oncology company, which engages in the development of innovative therapies for the treatment of cancer. Its pipeline is comprised of TTI-621, TTI-622, and TTI-2341(EGFR Inhibitor). The company was founded on March 31, 2004 and is headquartered in Toronto, Canada.